
    
      Study 20140114 will continue to follow subjects with GCTB who were treated in Study 20062004
      and remained on the study at the completion of Study 20062004 for an additional 5 years on
      long-term safety follow up. Collection of long-term safety information will include adverse
      events of interest and all treatment-emergent adverse events and serious adverse events
    
  